Scott Eisenhower
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott Eisenhower has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Monsanto
Ronin Institute
1 shared publication - Lokesh Agrawal
Universidad Integral del Caribe y América Latina, Kaminda Cas Grandi #79, Willemstad, Curacao
1 shared publication - Min-Hua Chen
Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan City 320314, Taiwan
1 shared publication - Rajkumar Singh Kalra
Immune Signal Unit, Okinawa Institute of Science and Technology Graduate University, Okinawa, Japan
1 shared publication - Ranjith Kumar Bakku
Faculty of Engineering Information and Systems, University of Tsukuba, 1-1-1 Tenodai, Tsukuba 305-8572, Japan
1 shared publication - Thanasis Poullikkas
Human Biology, School of Integrative and Global Majors, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-0006, Japan
1 shared publication
Latest Publications
- Open Access
- 11 January 2021
- Published by MDPI AG in Antibodies
- Vol. 10 (1) , 3
Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus for which no known effective antiviral drugs are available. In the present study, to accelerate the discovery of potential drug candidates, bioinformatics-based in silico drug discovery approaches are utilized. We performed multiple sequence alignments of the Spike (S) protein with 75 sequences of different viruses from the Orthocoronavirinae subfamily. This provided us with insights into the evolutionarily conserved domains that can be targeted using drugs or specific antibodies. Further, we analyzed the mechanism of SARS-CoV-2 core proteins, i.e., S and RdRp (RNA-dependent RNA polymerase), to elucidate how the virus infection can utilize hemoglobin to decrease the blood oxygen level. Moreover, after a comprehensive literature survey, more than 60 antiviral drugs were chosen. The candidate drugs were then ranked based on their potential to interact with the Spike and RdRp proteins of SARS-CoV-2. The present multidimensional study further advances our understanding of the novel viral molecular targets and potential of computational approaches for therapeutic assessments. The present study can be a steppingstone in the selection of potential drug candidates to be used either as a treatment or as a reference point when designing a new drug/antibody/inhibitory peptide/vaccine against SARS-CoV-2.
- 11 January 2021
- Published by MDPI AG in Antibodies
- Vol. 10 (1) , 3
Open AccessViroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus for which no known effective antiviral drugs are available. In the present study, to accelerate the discovery of potential drug candidates, bioinformatics-based in silico drug discovery approaches are utilized. We performed multiple sequence alignments of the Spike (S) protein with 75 sequences of different viruses from the Orthocoronavirinae subfamily. This provided us with insights into the evolutionarily conserved domains that can be targeted using drugs or specific antibodies. Further, we analyzed the mechanism of SARS-CoV-2 core proteins, i.e., S and RdRp (RNA-dependent RNA polymerase), to elucidate how the virus infection can utilize hemoglobin to decrease the blood oxygen level. Moreover, after a comprehensive literature survey, more than 60 antiviral drugs were chosen. The candidate drugs were then ranked based on their potential to interact with the Spike and RdRp proteins of SARS-CoV-2. The present multidimensional study further advances our understanding of the novel viral molecular targets and potential of computational approaches for therapeutic assessments. The present study can be a steppingstone in the selection of potential drug candidates to be used either as a treatment or as a reference point when designing a new drug/antibody/inhibitory peptide/vaccine against SARS-CoV-2.